Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence

Cancer Immunology, Immunotherapy

Volumn 64, Issue 4, 2015, Pages 467-478

  Okroj, Marcin ^a,b   Holmquist, Emelie ^a   Nilsson, Elise ^c   Anagnostaki, Lola ^b   Jirström, Karin ^d   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b Region Skåne ^*  (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Complement system; Immunohistochemistry; Innate immunity; Tissue microarrays

Indexed keywords

COMPLEMENT FACTOR I; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; CFI PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER GRADING; CANCER INFILTRATION; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CANCER TISSUE; CELL INFILTRATION; CELL LEVEL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MITOSIS RATE; MOLECULAR WEIGHT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; STROMA CELL; TISSUE MICROARRAY; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMPLEMENT FACTOR I; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84925541793     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1658-8     Document Type: Article

References (35)

1. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785–797. doi:10.1038/ni.1923
2. Okroj M, Osterborg A, Blom AM (2013) Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat Rev 39:632–639. doi:10.1016/j.ctrv.2012.10.008
3. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36:929–939
4. Mark L, Lee WH, Spiller OB, Proctor D, Blackbourn DJ, Villoutreix BO, Blom AM (2004) The Kaposi’s sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J Biol Chem 279:45093–45101
5. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178:5991–5998
6. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9:1225–1235. doi:10.1038/ni.1655
7. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R (2012) Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J Immunol 189:4674–4683. doi:10.4049/jimmunol.1201654
8. Schlaf G, Demberg T, Beisel N, Schieferdecker HL, Gotze O (2001) Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 38:231–239
9. Holers VM (2014) Complement and its receptors: new insights into human disease. Ann Rev Immunol 32:433–459. doi:10.1146/annurev-immunol-032713-120154
10. Stover C (2010) Dual role of complement in tumour growth and metastasis (review). Int J Mol Med 25:307–313
11. Minta JO, Fung M, Paramaswara B (1998) Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6. Biochim Biophys Acta 1442:286–295
12. Vetvicka V, Reed W, Hoover ML, Ross GD (1993) Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3. J Immunol 150:4052–4060
13. Gasque P, Julen N, Ischenko AM, Picot C, Mauger C, Chauzy C, Ripoche J, Fontaine M (1992) Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149:1381–1387
14. Legoedec J, Gasque P, Jeanne JF, Fontaine M (1995) Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 25:3460–3466. doi:10.1002/eji.1830251238
15. Okroj M, Hsu YF, Ajona D, Pio R, Blom AM (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45:169–179
16. Riihila P, Nissinen L, Farshchian M, Kivisaari A, Ala-Aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kahari VM (2015) Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 135:579–588. doi:10.1038/jid.2014.376
17. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, Fremeaux-Bacchi V, Trouw LA, Blom AM (2007) A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 44:1835–1844. doi:10.1016/j.molimm.2006.10.005
18. Malm S, Jusko M, Eick S, Potempa J, Riesbeck K, Blom AM (2012) Acquisition of complement inhibitor serine protease factor I and its cofactors C4b-binding protein and factor H by Prevotella intermedia. PLoS ONE 7:e34852. doi:10.1371/journal.pone.0034852
19. Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM (2010) Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 40:172–185. doi:10.1002/eji.200939280
20. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034
21. Nilsson SC, Blom AM (2014) Purification and functional characterization of factor I. Methods Mol Biol 1100:177–188. doi:10.1007/978-1-62703-724-2_15
22. Greenwood FC, Hunter WM, Glover JS (1963) The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J 89:114–123
23. Mohlin FC, Blom AM (2014) Purification and functional characterization of C4b-binding protein (C4BP). Methods Mol Biol 1100:169–176. doi:10.1007/978-1-62703-724-2_14
24. Helczynska K, Larsson AM, Mengelbier LH, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K (2008) Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68:9212–9220. doi:10.1158/0008-5472.CAN-08-1135
25. Svensson KJ, Christianson HC, Kucharzewska P, Fagerstrom V, Lundstedt L, Borgquist S, Jirstrom K, Belting M (2011) Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol 39:1421–1428. doi:10.3892/ijo.2011.1164
26. Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K (2008) Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61:197–203. doi:10.1136/jcp.2006.040378
27. Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G (2005) Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23:4695–4704. doi:10.1200/JCO.2005.08.126
28. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14:22–29. doi:10.1016/j.jmoldx.2011.08.002
29. Blom AM, Kask L, Dahlbäck B (2003) CCP1-4 of the C4b-binding protein a-chain are required for factor I mediated cleavage of C3b. Mol Immunol 39:547–556
30. Cui T, Chen Y, Knösel T, Yang L, Zöller K, Galler K, Berndt A, Mihlan M, Zipfel PF, Petersen I (2011) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39:161–168. doi:10.3892/ijo.2011.1010
31. Okroj M, Corrales L, Stokowska A, Pio R, Blom AM (2009) Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother 58:1771–1880. doi:10.1007/s00262-009-0685-8
32. Ullman CG, Chamberlain D, Ansari A, Emery VC, Haris PI, Sim RB, Perkins SJ (1998) Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Mol Immunol 35:503–512
33. O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110. doi:10.1158/1078-0432.CCR-10-1533
34. Munn LL (2003) Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8:396–403
35. Ross GD, Vĕtvicka V (1993) CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 92:181–184